MA49704A - Dérivés d'acide biliaire à marquage isotopique - Google Patents
Dérivés d'acide biliaire à marquage isotopiqueInfo
- Publication number
- MA49704A MA49704A MA049704A MA49704A MA49704A MA 49704 A MA49704 A MA 49704A MA 049704 A MA049704 A MA 049704A MA 49704 A MA49704 A MA 49704A MA 49704 A MA49704 A MA 49704A
- Authority
- MA
- Morocco
- Prior art keywords
- isotopic
- labeled
- acid derivatives
- biliary acid
- biliary
- Prior art date
Links
- 239000003613 bile acid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J17/005—Glycosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762536326P | 2017-07-24 | 2017-07-24 | |
| US201762536609P | 2017-07-25 | 2017-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49704A true MA49704A (fr) | 2021-03-31 |
Family
ID=65041285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049704A MA49704A (fr) | 2017-07-24 | 2018-07-23 | Dérivés d'acide biliaire à marquage isotopique |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11472831B2 (fr) |
| EP (1) | EP3658150A4 (fr) |
| JP (1) | JP2020528892A (fr) |
| KR (1) | KR20200031145A (fr) |
| CN (1) | CN111050772A (fr) |
| AU (1) | AU2018307611A1 (fr) |
| BR (1) | BR112020001362A2 (fr) |
| CA (1) | CA3070837A1 (fr) |
| IL (1) | IL272119A (fr) |
| MA (1) | MA49704A (fr) |
| MX (1) | MX2020000873A (fr) |
| WO (1) | WO2019023103A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202021595A (zh) | 2018-08-10 | 2020-06-16 | 德商菲尼克斯製藥股份有限公司 | 用於預防及治療困難梭狀芽孢桿菌關聯疾病之異石膽酸或異別石膽酸及其氘化衍生物 |
| US20230146782A1 (en) * | 2019-08-06 | 2023-05-11 | Du Jessica Xinyun | Deoxycholic acid compounds, pharmaceutical compositions and uses thereof |
| CN112898369B (zh) * | 2019-12-04 | 2024-09-17 | 博瑞生物医药(苏州)股份有限公司 | 用于制备奥贝胆酸的方法 |
| JP7755328B2 (ja) * | 2021-09-09 | 2025-10-16 | 国立大学法人九州大学 | 重水素富化組成物、重水素置換されたカルボン酸の製造方法、反応促進剤及びカルボン酸を酸無水物に変換する化合物の使用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10113257C1 (de) | 2001-03-19 | 2002-11-14 | Inst Mikrotechnik Mainz Gmbh | Elektrophoresevorrichtung und ihre Verwendung |
| DK2040713T3 (da) | 2006-06-27 | 2014-09-29 | Intercept Pharmaceuticals Inc | Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande |
| SG10201400162QA (en) | 2008-11-19 | 2014-05-29 | Intercept Pharmaceuticals Inc | Tgr5 modulators and methods of use thereof |
| WO2013037482A1 (fr) * | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Agonistes du récepteur du farnésoïde x pour le traitement et la prévention du cancer |
| SG10201607230SA (en) | 2012-06-19 | 2016-10-28 | Intercept Pharmaceuticals Inc | Preparation, Uses And Solid Forms Of Obeticholic Acid |
| BR112015009395A2 (pt) * | 2012-10-26 | 2017-07-04 | Intercept Pharmaceuticals Inc | processo para preparação de derivados do ácido biliar |
| DK2997035T3 (en) | 2013-05-14 | 2018-07-02 | Intercept Pharmaceuticals Inc | 11-HYDROXY-6-SUBSTITUTED BALIC ACID DERIVATIVES AND AMINO ACID CONJUGATES THEREOF AS FARNESOID X RECEPTOR MODULATORS |
| US20150112089A1 (en) | 2013-10-22 | 2015-04-23 | Metselex, Inc. | Deuterated bile acids |
| CN105985396A (zh) * | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| WO2016168553A1 (fr) * | 2015-04-17 | 2016-10-20 | Concert Pharmaceuticals, Inc. | Acide obéticholique deutéré |
| PE20180690A1 (es) * | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| CN108348530B (zh) | 2015-10-07 | 2023-09-29 | 英特塞普特医药品公司 | 法尼醇x受体调节剂 |
| US10364267B2 (en) | 2016-02-23 | 2019-07-30 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| CN109467585A (zh) | 2016-03-11 | 2019-03-15 | 深圳市塔吉瑞生物医药有限公司 | 用于预防或治疗fxr-介导疾病的胆烷酸化合物 |
-
2018
- 2018-07-23 CA CA3070837A patent/CA3070837A1/fr not_active Abandoned
- 2018-07-23 EP EP18838551.2A patent/EP3658150A4/fr not_active Withdrawn
- 2018-07-23 KR KR1020207004777A patent/KR20200031145A/ko not_active Withdrawn
- 2018-07-23 MX MX2020000873A patent/MX2020000873A/es unknown
- 2018-07-23 WO PCT/US2018/043239 patent/WO2019023103A1/fr not_active Ceased
- 2018-07-23 CN CN201880054875.6A patent/CN111050772A/zh active Pending
- 2018-07-23 US US16/632,093 patent/US11472831B2/en active Active
- 2018-07-23 MA MA049704A patent/MA49704A/fr unknown
- 2018-07-23 AU AU2018307611A patent/AU2018307611A1/en not_active Abandoned
- 2018-07-23 BR BR112020001362-5A patent/BR112020001362A2/pt not_active Application Discontinuation
- 2018-07-23 JP JP2020503292A patent/JP2020528892A/ja active Pending
-
2020
- 2020-01-19 IL IL272119A patent/IL272119A/en unknown
-
2022
- 2022-09-07 US US17/939,326 patent/US20230057232A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019023103A1 (fr) | 2019-01-31 |
| CN111050772A (zh) | 2020-04-21 |
| EP3658150A4 (fr) | 2021-03-31 |
| MX2020000873A (es) | 2020-07-22 |
| AU2018307611A1 (en) | 2020-02-06 |
| US20200165290A1 (en) | 2020-05-28 |
| US20230057232A1 (en) | 2023-02-23 |
| IL272119A (en) | 2020-03-31 |
| KR20200031145A (ko) | 2020-03-23 |
| JP2020528892A (ja) | 2020-10-01 |
| CA3070837A1 (fr) | 2019-01-31 |
| US11472831B2 (en) | 2022-10-18 |
| BR112020001362A2 (pt) | 2020-08-11 |
| EP3658150A1 (fr) | 2020-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49421A (fr) | Formulations d'arn | |
| EP3517528A4 (fr) | Sel d'addition d'acide de dérivé de benzimidazole | |
| EP3277381C0 (fr) | Dérivés de nitrobenzyle d'agents anticancéreux | |
| EP3443092A4 (fr) | Compositions de conjugués d'acides nucléiques ciblés | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| EP3426242A4 (fr) | Icaritine et dérivés d'icaritine | |
| EP3416647A4 (fr) | Iminopyrimidinones substituées par n3 à titre d'agents antipaludéens | |
| EP3820980A4 (fr) | Compositions d'esterquats | |
| EP3408254A4 (fr) | Sels de l'acide 5-aminolévulinique et dérivés | |
| EP3600279A4 (fr) | Formulations d'acide 1-amino-1-cyclopropanecaboxylique | |
| EP3302061A4 (fr) | Compositions d'urée à libération prolongée | |
| MA49704A (fr) | Dérivés d'acide biliaire à marquage isotopique | |
| EP3600280A4 (fr) | Formulations de chlorhydrate d'acide 1-amino-1-cyclopropanecarboxylique | |
| EP4043450A4 (fr) | Dérivés 2h-benzopyrane utilisables en tant qu'inhibiteurs de crac | |
| EP3452441A4 (fr) | Dérivés d'acide alpha-truxillique et compositions pharmaceutiques associées | |
| EP3645548A4 (fr) | Procédés de préparation d'acides biliaires | |
| EP4013441A4 (fr) | Formulations de larazotide | |
| EP3316677A4 (fr) | Activateur de passage d'acide jasmonique | |
| EP3955910A4 (fr) | Formulations à libération prolongée | |
| EP3444345A4 (fr) | Dérivé d'arnmicro-143 | |
| EP3377111A4 (fr) | Promédicaments d'amine de composés pharmaceutiques | |
| EP3681950A4 (fr) | Pulvérisation d'acide tranexamique pour arthroplastie du genou | |
| MA56504A (fr) | Dérivés de pyridin-3-yle |